Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.

Yubero A, Barquín A, Estévez P, Pajares B, Sánchez L, Reche P, Alarcón J, Calzas J, Gaba L, Fuentes J, Santaballa A, Salvador C, Manso L, Herrero A, Taus Á, Márquez R, Madani J, Merino M, Marquina G, Casado V, Constenla M, Gutiérrez M, Dosil A, González-Martín A

Open source

DOI: 10.1186/s12885-022-10191-5
Published: 2022 Nov 8
Container: BMC cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1186/s12885-022-10191-5,
  title = {Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.},
  author = {Yubero A and Barquín A and Estévez P and Pajares B and Sánchez L and Reche P and Alarcón J and Calzas J and Gaba L and Fuentes J and Santaballa A and Salvador C and Manso L and Herrero A and Taus Á and Márquez R and Madani J and Merino M and Marquina G and Casado V and Constenla M and Gutiérrez M and Dosil A and González-Martín A},
  year = {2022},
  journal = {BMC cancer},
  doi = {10.1186/s12885-022-10191-5},
  url = {https://doi.org/10.1186/s12885-022-10191-5}
}

RIS

TY  - JOUR
TI  - Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
AU  - Yubero A
AU  - Barquín A
AU  - Estévez P
AU  - Pajares B
AU  - Sánchez L
AU  - Reche P
AU  - Alarcón J
AU  - Calzas J
AU  - Gaba L
AU  - Fuentes J
AU  - Santaballa A
AU  - Salvador C
AU  - Manso L
AU  - Herrero A
AU  - Taus Á
AU  - Márquez R
AU  - Madani J
AU  - Merino M
AU  - Marquina G
AU  - Casado V
AU  - Constenla M
AU  - Gutiérrez M
AU  - Dosil A
AU  - González-Martín A
PY  - 2022
JO  - BMC cancer
DO  - 10.1186/s12885-022-10191-5
UR  - https://doi.org/10.1186/s12885-022-10191-5
ER  -

APA

A, Y., A, B., P, E., B, P., L, S., P, R., J, A., J, C., L, G., J, F., A, S., C, S., L, M., A, H., Á, T., R, M., J, M., M, M., G, M., V, C., M, C., M, G., A, D., & A, G. (2022). Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.. BMC cancer. https://doi.org/10.1186/s12885-022-10191-5

Source records

pubmed · retrieved 2026-09-26T14:12:37.301Z
europe-pmc · retrieved 2026-09-26T14:12:37.296Z
doaj · retrieved 2026-09-26T14:12:37.277Z